ArticleNature2021
In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains.
Open access · bronzeAbstract read
In one paragraph
Article in Nature, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 169 papers.
0numbers the graph read from it
0cells of the map it votes in
169citing papers in PubMed
16.5field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
169 citing papers in PubMed, 260 citations in OpenAlex.
- Safety, Tolerability, and Pharmacokinetics of Anti-SARS-CoV-2 Immunoglobulin Intravenous (Human) Investigational Product (COVID-HIGIV) in Healthy Adults: a Randomized, Controlled, Double-Blinded, Phase 1 Study.Antimicrobial agents and chemotherapy · 2023Trial
- Phase 1 study of safety, pharmacokinetics, and antiviral activity of SARS-CoV-2 neutralizing monoclonal antibody ABBV-47D11 in patients with COVID-19.Pharmacology research & perspectives · 2023Trial
- Efficacy and Safety of SARS-CoV-2 Neutralizing Antibody JS016 in Hospitalized Chinese Patients with COVID-19: a Phase 2/3, Multicenter, Randomized, Open-Label, Controlled Trial.Antimicrobial agents and chemotherapy · 2022Trial
- Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.Lancet (London, England) · 2022Trial
- Responses to a Neutralizing Monoclonal Antibody for Hospitalized Patients With COVID-19 According to Baseline Antibody and Antigen Levels : A Randomized Controlled Trial.Annals of internal medicine · 2022Trial
- Emulation of a Target Trial From Observational Data to Compare Effectiveness of Casirivimab/Imdevimab and Bamlanivimab/Etesevimab for Early Treatment of Non-Hospitalized Patients With COVID-19.Frontiers in immunology · 2022Trial
- Nanobodies targeting SARS-CoV-2 variants.Acta pharmaceutica Sinica. B · 2026Review
- Evaluating Memory B Cell Cross-Reactivity Between Ancestral and Future SARS-CoV-2 Variants-Evidence for Original Antigenic Sin.Vaccines · 2026Article
- Orphan broadly RBD-binding antibodies annotate three remaining conserved RBD epitopes along SARS-CoV-2 evolution.Nature communications · 2025Article
- Mapping of human monoclonal antibody responses to XBB.1.5 COVID-19 monovalent vaccines: a B cell analysis.The Lancet. Microbe · 2025Observational
- Review
- COVID-19 clinical presentation, management, and epidemiology: a concise compendium.Frontiers in public health · 2025Review
- Article
- A trivalent mucosal vaccine encoding phylogenetically inferred ancestral RBD sequences confers pan-Sarbecovirus protection in mice.Cell host & microbe · 2024Article
- In vivo delivery of engineered synthetic DNA-encoded SARS-CoV-2 monoclonal antibodies for pre-exposure prophylaxis in non-human primates.Emerging microbes & infections · 2024Article
- Infiltrating monocytes drive cardiac dysfunction in a cardiomyocyte-restricted mouse model of SARS-CoV-2 infection.Journal of virology · 2024Article
- Article
- Article
- A viral assembly inhibitor blocks SARS-CoV-2 replication in airway epithelial cells.Communications biology · 2024Article
- SARS-CoV-2 resistance to monoclonal antibodies and small-molecule drugs.Cell chemical biology · 2024Review
109 more citing papers are in PubMed but not listed here.
Corrections and comments
- Update of
Authors and funding
34 authors at 7 institutions in 3 countries.
Rita E Chen *Department of Medicine, Washington University School of Medicine, St Louis, MO, USA.
Emma S Winkler *Department of Medicine, Washington University School of Medicine, St Louis, MO, USA.
James Brett Case *Department of Medicine, Washington University School of Medicine, St Louis, MO, USA.ORCID http://orcid.org/0000-0001-7331-5511
Ishmael D AziatiDepartment of Medicine, Washington University School of Medicine, St Louis, MO, USA.
Traci L BrickerDepartment of Medicine, Washington University School of Medicine, St Louis, MO, USA.
Astha JoshiDepartment of Medicine, Washington University School of Medicine, St Louis, MO, USA.ORCID http://orcid.org/0000-0003-4914-8228
Tamarand L DarlingDepartment of Medicine, Washington University School of Medicine, St Louis, MO, USA.
Baoling YingDepartment of Medicine, Washington University School of Medicine, St Louis, MO, USA.
John M ErricoDepartment of Pathology and Immunology, Washington University School of Medicine, St Louis, MO, USA.ORCID http://orcid.org/0000-0002-4452-8152
Swathi ShrihariDepartment of Medicine, Washington University School of Medicine, St Louis, MO, USA.
Laura A VanBlarganDepartment of Medicine, Washington University School of Medicine, St Louis, MO, USA.
Xuping XieDepartment of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston, TX, USA.ORCID http://orcid.org/0000-0003-0918-016X
Pavlo GilchukVanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN, USA.
Seth J ZostVanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN, USA.ORCID http://orcid.org/0000-0001-6712-5076
Lindsay DroitDepartment of Molecular Microbiology, Washington University School of Medicine, St Louis, MO, USA.
Zhuoming LiuDepartment of Molecular Microbiology, Washington University School of Medicine, St Louis, MO, USA.ORCID http://orcid.org/0000-0001-8198-0976
Spencer StumpfDepartment of Molecular Microbiology, Washington University School of Medicine, St Louis, MO, USA.
David WangDepartment of Molecular Microbiology, Washington University School of Medicine, St Louis, MO, USA.
Scott A HandleyDepartment of Pathology and Immunology, Washington University School of Medicine, St Louis, MO, USA.
W Blaine StineAbbVie Bioresearch Center, Worcester, MA, USA.
Pei-Yong ShiDepartment of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston, TX, USA.ORCID http://orcid.org/0000-0001-5553-1616
Meredith E Davis-GardnerCenter for Childhood Infections and Vaccines of Children's Healthcare of Atlanta, Department of Pediatrics, Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA, USA.
Mehul S SutharCenter for Childhood Infections and Vaccines of Children's Healthcare of Atlanta, Department of Pediatrics, Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA, USA.
Miguel Garcia KnightDepartment of Microbiology and Immunology, University of California San Francisco, San Francisco, CA, USA.
Raul AndinoDepartment of Microbiology and Immunology, University of California San Francisco, San Francisco, CA, USA.ORCID http://orcid.org/0000-0001-5503-9349
Charles Y ChiuDepartment of Laboratory Medicine, University of California San Francisco, San Francisco, CA, USA.ORCID http://orcid.org/0000-0003-2915-2094
Ali H EllebedyDepartment of Pathology and Immunology, Washington University School of Medicine, St Louis, MO, USA.ORCID http://orcid.org/0000-0002-6129-2532
Daved H FremontDepartment of Pathology and Immunology, Washington University School of Medicine, St Louis, MO, USA.ORCID http://orcid.org/0000-0002-8544-2689
Sean P J WhelanDepartment of Molecular Microbiology, Washington University School of Medicine, St Louis, MO, USA.ORCID http://orcid.org/0000-0003-1564-8590
James E CroweVanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN, USA.ORCID http://orcid.org/0000-0002-0049-1079
Lisa PurcellVir Biotechnology, St Louis, MO, USA.
Davide CortiHumabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.ORCID http://orcid.org/0000-0002-5797-1364
Adrianus C M BoonDepartment of Medicine, Washington University School of Medicine, St Louis, MO, USA.ORCID http://orcid.org/0000-0002-4700-8224
Michael S DiamondDepartment of Medicine, Washington University School of Medicine, St Louis, MO, USA. diamond@wusm.wustl.edu.ORCID http://orcid.org/0000-0002-8791-3165
Washington University in St. Louis · USUniversity of California, San Francisco · USVanderbilt University Medical Center · USEmory University · USThe University of Texas Medical Branch at Galveston · USAbbVie (United States) · USVir Biotechnology (Switzerland) · CH
Funding
COLLABORATIVE INFLUENZA VACCINE INNOVATION CENTER: UNIVERSAL INFLUENZA VACCINE RESEARCH75N93019C00051 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI KRAMMER, FLORIAN · 2019 to 2025
$105.4MTRAINING PROGRAM IN IMMUNOLOGY AND IMMUNOGENETICST32AI007163 · NIAID · WASHINGTON UNIVERSITY · PI Kenneth M Murphy, Kodi S Ravichandran · 1985 to 2026
$14.8MB-CELL EPITOPE DISCOVERY AND MECHANISMS OF ANTIBODY PROTECTION: Modification for SARS-CoV2 Research75N93019C00074 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI CROWE, JAMES E · 2019 to 2024
$10.2MEmerging infections: surveillance, epidemiology and pathogenesisU01AI151810 · NIAID · WASHINGTON UNIVERSITY · PI Adrianus CM Boon, DAVID WANG · 2020 to 2026
$10.0MHuman antibody-based countermeasures against the Wuhan Coronavirus SARS-CoV-2R01AI157155 · NIAID · WASHINGTON UNIVERSITY · PI BARIC, RALPH S, CROWE, JAMES E · 2020 to 2024
$6.0MProgramming Durable Immune Responses To VaccinationU01AI141990 · NIAID · WASHINGTON UNIVERSITY · PI Ali Hassan Ellebedy · 2019 to 2026
$5.3MChildhood Infections Research ProgramT32AI095202 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI JAMES E CASSAT · 2011 to 2026
$4.2MThe Role of IFI35 in Innate Immunity and Influenza PathogenesisR01AI118938 · NIAID · WASHINGTON UNIVERSITY · PI BOON, ADRIANUS CM · 2016 to 2020
$1.9MRegulation of Antiviral Responses in Plasmacytoid Dendritic Cells to Chikungunya Virus by the Gut MicrobiotaF30AI152327 · NIAID · WASHINGTON UNIVERSITY · PI WINKLER, EMMA SUENING · 2021 to 2022
$84kNIAID NIH HHS 75N93019C00051NIAID NIH HHS 75N93019C00074NIAID NIH HHS F30 AI152327NIAID NIH HHS HHSN272201400006CNIAID NIH HHS HHSN272201400008CNIAID NIH HHS R01 AI118938NIAID NIH HHS R01 AI157155NIAID NIH HHS T32 AI007163NIAID NIH HHS T32 AI095202NIAID NIH HHS U01 AI141990NIAID NIH HHS U01 AI151810
Abstract
Rapidly emerging SARS-CoV-2 variants jeopardize antibody-based countermeasures. Although cell culture experiments have demonstrated a loss of potency of several anti-spike neutralizing antibodies against variant strains of SARS-CoV-2
Indexed as
Neutralization TestsAngiotensin-Converting Enzyme 2AnimalsAntibodies, MonoclonalAntibodies, NeutralizingAntibodies, ViralChlorocebus aethiopsCOVID-19FemaleHumansMaleMesocricetusMiceMice, TransgenicPost-Exposure ProphylaxisPre-Exposure ProphylaxisACE2 protein, humanAngiotensin-Converting Enzyme 2Antibodies, MonoclonalAntibodies, NeutralizingAntibodies, ViralHPN protein, humanSerine EndopeptidasesSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.